PPAR-γ as a therapeutic target in cardiovascular disease: Evidence and uncertainty

Journal of Lipid Research

Volumn 53, Issue 9, 2012, Pages 1738-1754

  Huang, Janice V ^a,b   Greyson, Clifford R ^a,b   Schwartz, Gregory G ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Diabetes; Fatty acids; Insulin resistance; Peroxisome proliferator activated receptor gamma; Randomized clinical trials

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALEGLITAZAR; BALAGLITAZONE; FATTY ACID; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZAR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIGLITAZAR; ION CHANNEL; LIPOPROTEIN; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; RIVOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TESAGLITAZAR; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG TARGETING; ELECTROPHYSIOLOGY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LABORATORY DIAGNOSIS; LIPOPROTEIN METABOLISM; MONOTHERAPY; MORBIDITY; NONHUMAN; OBSERVATIONAL STUDY; PLASMA VOLUME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESTENOSIS; REVIEW; TREATMENT RESPONSE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MOLECULAR TARGETED THERAPY; PPAR GAMMA; UNCERTAINTY;

EID: 84864864825     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R024505     Document Type: Review

References (217)

1. Adams, M., C. T. Montague, J. B. Prins, J. C. Holder, S. A. Smith, L. Sanders, J. E. Digby, C. P. Sewter, M. A. Lazar, V. K. Chatterjee, et al. 1997. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100:3149-3153. (Pubitemid 28022853)
2. Festuccia, W. T., P. G. Blanchard, V. Turcotte, M. Laplante, M. Sariahmetoglu, D. N. Brindley, and Y. Deshaies. 2009. Depot-specific effects of the PPARgamma agonist rosiglitazone on adipose tissue glucose uptake and metabolism. J. Lipid Res. 50:1185-1194.
3. Gray, S. L., and A. J. Vidal-Puig. 2007. Adipose tissue expandability in the maintenance of metabolic homeostasis. Nutr. Rev. 65: S7-S12.
4. Sharma, A. M., and B. Staels. 2007. Review: peroxisome proliferator- activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab. 92:386-395.
5. Weisberg, S. P., D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante, Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112: 1796-1808. (Pubitemid 38063703)
6. Hajer, G. R., T. W. van Haeften, and F. L. Visseren. 2008. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 29:2959-2971.
7. Doshi, K. B., S. R. Kashyap, D. M. Brennan, B. M. Hoar, L. Cho, and B. J. Hoogwerf. 2009. All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study. Diabetes Obes. Metab. 11:102-108.
8. Malik, S., N. D. Wong, S. S. Franklin, T. V. Kamath, G. J. L'Italien, J. R. Pio, and G. R. Williams. 2004. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 110: 1245-1250. (Pubitemid 39202340)
9. Ninomiya, J. K., G. L'Italien, M. H. Criqui, J. L. Whyte, A. Gamst, and R. S. Chen. 2004. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 109:42-46. (Pubitemid 38056019)
10. Bajaj, M., R. Baig, S. Suraamornkul, L. J. Hardies, D. K. Coletta, G. W. Cline, A. Monroy, S. Koul, A. Sriwijitkamol, N. Musi, et al. 2010. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 95:1916-1923.
11. Mayerson, A. B., R. S. Hundal, S. Dufour, V. Lebon, D. Befroy, G. W. Cline, S. Enocksson, S. E. Inzucchi, G. I. Shulman, and K. F. Petersen. 2002. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:797-802. (Pubitemid 34760191)
12. McLaughlin, T. M., T. Liu, G. Yee, F. Abbasi, C. Lamendola, G. M. Reaven, P. Tsao, S. W. Cushman, and A. Sherman. 2010. Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue. Obesity (Silver Spring). 18: 926-931.
13. Miyazaki, Y., A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, K. Cusi, L. J. Mandarino, and R. A. DeFronzo. 2002. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87:2784-2791. (Pubitemid 34655345)
14. Nam, J. S., J. Y. Nam, J. S. Yoo, M. Cho, J. S. Park, C. W. Ahn, B. S. Cha, E. J. Lee, S. K. Lim, K. R. Kim, et al. 2010. The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with Type 2 diabetes. Diabet. Med. 27:30-36.
15. Derosa, G., and S. A. Salvadeo. 2008. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Curr. Clin. Pharmacol. 3:77-84.
16. Martens, F. M., F. L. Visseren, J. Lemay, E. J. de Koning, and T. J. Rabelink. 2002. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 62:1463-1480. (Pubitemid 34804155)
17. Riera-Guardia, N., and D. Rothenbacher. 2008. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes. Metab. 10:367-375. (Pubitemid 351524284)
18. Wang, N., R. Yin, Y. Liu, G. Mao, and F. Xi. 2011. Role of peroxisome proliferator-activated receptor-gamma in atherosclerosis: an update. Circ. J. 75:528-535.
19. Sigmund, C. D. 2010. Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency. Hypertension. 55:437-444.
20. Duan, S. Z., M. G. Usher, and R. M. Mortensen. 2008. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ. Res. 102:283-294. (Pubitemid 351271648)
21. Giaginis, C., G. Tsourouflis, and S. Theocharis. 2008. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury. Curr. Mol. Med. 8:562-579.
22. Rubenstrunk, A., R. Hanf, D. W. Hum, J. C. Fruchart, and B. Staels. 2007. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta. 1771:1065-1081. (Pubitemid 47208546)
23. Goldberg, R. B., D. M. Kendall, M. A. Deeg, J. B. Buse, A. J. Zagar, J. A. Pinaire, M. H. Tan, M. A. Khan, A. T. Perez, and S. J. Jacober. 2005. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 28:1547-1554. (Pubitemid 40923063)
24. Lu, L., M. J. Reiter, Y. Xu, A. Chicco, C. R. Greyson, and G. G. Schwartz. 2008. Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs. Diabetologia. 51:675-685.
25. Hancox, J. C. 2011. Cardiac ion channel modulation by the hypoglycaemic agent rosiglitazone. Br. J. Pharmacol. 163:496-498.
26. Sarraf, M., L. Lu, S. Ye, M. J. Reiter, C. R. Greyson, and G. G. Schwartz. 2012. Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fi- brillation in pigs. Cardiovasc. Drugs Ther. 26: 195-204.
27. Thorp, E., G. Kuriakose, Y. M. Shah, F. J. Gonzalez, and I. Tabas. 2007. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Circulation. 116: 2182-2190. (Pubitemid 350060356)
28. Ho-Tin-Noé, B., D. J. Le, D. Gomez, L. Louedec, R. Vranckx, M. El-Bouchtaoui, L. Legres, O. Meilhac, and J. B. Michel. 2011. Early atheroma-derived agonists of peroxisome proliferator-activated receptor-gamma trigger intramedial angiogenesis in a smooth muscle cell-dependent manner. Circ. Res. 109:1003-1014.
29. Amin, R. H., S. T. Mathews, H. S. Camp, L. Ding, and T. Leff. 2010. Selective activation of PPARgamma in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance. Am. J. Physiol. Endocrinol. Metab. 298:E28-E37.
30. He, W., Y. Barak, A. Hevener, P. Olson, D. Liao, J. Le, M. Nelson, E. Ong, J. M. Olefsky, and R. M. Evans. 2003. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA. 100:15712-15717. (Pubitemid 38021055)
31. Hevener, A. L., W. He, Y. Barak, J. Le, G. Bandyopadhyay, P. Olson, J. Wilkes, R. M. Evans, and J. Olefsky. 2003. Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 9:1491-1497. (Pubitemid 38004776)
32. Savage, D. B., G. D. Tan, C. L. Acerini, S. A. Jebb, M. Agostini, M. Gurnell, R. L. Williams, A. M. Umpleby, E. L. Thomas, J. D. Bell, et al. 2003. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes. 52:910-917. (Pubitemid 36384259)
33. Perriello, G., S. Pampanelli, P. C. Di, and P. Brunetti. 2006. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabet. Med. 23: 246-252.
34. Pavo, I., G. Jermendy, T. T. Varkonyi, Z. Kerenyi, A. Gyimesi, S. Shoustov, M. Shestakova, M. Herz, D. Johns, B. J. Schluchter, et al. 2003. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 88: 1637-1645. (Pubitemid 36623381)
35. Herz, M., D. Johns, J. Reviriego, L. D. Grossman, C. Godin, S. Duran, F. Hawkins, H. Lochnan, F. Escobar-Jimenez, P. A. Hardin, et al. 2003. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin. Ther. 25:1074-1095. (Pubitemid 36532579)
36. Carey, D. G., G. J. Cowin, G. J. Galloway, N. P. Jones, J. C. Richards, N. Biswas, and D. M. Doddrell. 2002. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. [corrected] Obes. Res. 10:1008-1015. (Pubitemid 135688917)
37. D'Souza, A., M. Hussain, F. C. Howarth, N. M. Woods, K. Bidasee, and J. Singh. 2009. Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart. Mol. Cell. Biochem. 331: 89-116.
38. McGuire, D. K., L. K. Newby, M. V. Bhapkar, D. J. Moliterno, J. S. Hochman, W. W. Klein, W. D. Weaver, M. Pfisterer, R. Corbalan, M. Dellborg, et al. 2004. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am. Heart J. 147:246-252. (Pubitemid 38176824)
39. Ahmed, S., C. P. Cannon, S. A. Murphy, and E. Braunwald. 2006. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur. Heart J. 27:2323-2329. (Pubitemid 44453576)
40. Schwartz, G. G., A. G. Olsson, M. Szarek, and W. J. Sasiela. 2005. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care. 28:2508-2513. (Pubitemid 41384302)
41. Bartnik, M., K. Malmberg, A. Norhammar, A. Tenerz, J. Ohrvik, and L. Ryden. 2004. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur. Heart J. 25:1990-1997. (Pubitemid 39486017)
42. Stratton, I. M., A. I. Adler, H. A. Neil, D. R. Matthews, S. E. Manley, C. A. Cull, D. Hadden, R. C. Turner, and R. R. Holman. 2000. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 321:405-412. (Pubitemid 30609442)
43. Ferrannini, E., D. J. Betteridge, J. A. Dormandy, B. Charbonnel, R. G. Wilcox, R. Spanheimer, E. Erdmann, R. A. DeFronzo, and M. Laakso. 2011. High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive. Diabetes Obes. Metab. 13:759-764.
44. Patel, A., S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward, M. Marre, M. Cooper, P. Glasziou, D. Grobbee, et al. 2008. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358: 2560-2572. (Pubitemid 351831357)
45. Gerstein, H. C., M. E. Miller, R. P. Byington, D. C. Goff, Jr., J. T. Bigger, J. B. Buse, W. C. Cushman, S. Genuth, F. Ismail-Beigi, R. H. Grimm, Jr., et al. 2008. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358:2545-2559. (Pubitemid 351831356)
46. Duckworth, W., C. Abraira, T. Moritz, D. Reda, N. Emanuele, P. D. Reaven, F. J. Zieve, J. Marks, S. N. Davis, R. Hayward, et al. 2009. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360:129-139.
47. Frye, R. L., P. August, M. M. Brooks, R. M. Hardison, S. F. Kelsey, J. M. MacGregor, T. J. Orchard, B. R. Chaitman, S. M. Genuth, S. H. Goldberg, et al. 2009. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360: 2503-2515.
48. Sarafidis, P. A., and G. L. Bakris. 2007. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? J. Hum. Hypertens. 21: 12-19. (Pubitemid 44921815)
49. Staiger, H., K. Staiger, N. Stefan, H. G. Wahl, F. Machicao, M. Kellerer, and H. U. Haring. 2004. Palmitate-induced interleukin-6 expression in human coronary artery endothelial cells. Diabetes. 53:3209-3216. (Pubitemid 39564497)
50. Steinberg, H. O., M. Tarshoby, R. Monestel, G. Hook, J. Cronin, A. Johnson, B. Bayazeed, and A. D. Baron. 1997. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J. Clin. Invest. 100:1230-1239. (Pubitemid 27386309)
51. Steinberg, H. O., G. Paradisi, G. Hook, K. Crowder, J. Cronin, and A. D. Baron. 2000. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes. 49: 1231-1238. (Pubitemid 30439100)
52. Giacca, A., C. Xiao, A. I. Oprescu, A. C. Carpentier, and G. F. Lewis. 2011. Lipid-induced pancreatic beta-cell dysfunction: focus on in vivo studies. Am. J. Physiol. Endocrinol. Metab. 300:E255-E262.
53. Samuel, V. T., K. F. Petersen, and G. I. Shulman. 2010. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 375:2267-2277.
54. Savage, D. B., and R. K. Semple. 2010. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr. Opin. Lipidol. 21:329-336.
55. Charnock, J. S. 1994. Lipids and cardiac arrhythmia. Prog. Lipid Res. 33:355-385. (Pubitemid 24243352)
56. Pilz, S., H. Scharnagl, B. Tiran, B. Wellnitz, U. Seelhorst, B. O. Boehm, and W. Marz. 2007. Elevated plasma free fatty acids predict sudden cardiac death: a 6.85-year follow-up of 3315 patients after coronary angiography. Eur. Heart J. 28:2763-2769. (Pubitemid 350135527)
57. Golay, A., A. L. Swislocki, Y. D. Chen, and G. M. Reaven. 1987. Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism. 36:692-696. (Pubitemid 17100986)
58. Kashyap, S., R. Belfort, A. Gastaldelli, T. Pratipanawatr, R. Berria, W. Pratipanawatr, M. Bajaj, L. Mandarino, R. DeFronzo, and K. Cusi. 2003. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 52:2461-2474. (Pubitemid 37210533)
59. Mook, S., C. C. Halkes, S. Bilecen, and M. C. Cabezas. 2004. In vivo regulation of plasma free fatty acids in insulin resistance. Metabolism. 53:1197-1201. (Pubitemid 39140757)
60. Chaudhuri, A., J. Rosenstock, A. Digenio, L. Meneghini, P. Hollander, J. B. McGill, P. Dandona, J. Ilgenfritz, and M. Riddle. 2012. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metab. Res. Rev. 28:258-267.
61. Martens, F. M., F. L. Visseren, E. J. de Koning, and T. J. Rabelink. 2005. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J. Cardiovasc. Pharmacol. 46:773-778. (Pubitemid 44378249)
62. Miyazaki, Y., L. Glass, C. Triplitt, M. Matsuda, K. Cusi, A. Mahankali, S. Mahankali, L. J. Mandarino, and R. A. DeFronzo. 2001. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia. 44:2210-2219. (Pubitemid 34015474)
63. Abbasi, F., N. K. Lima, and G. M. Reaven. 2009. Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone. Metabolism. 58:373-378.
64. Brackenridge, A. L., N. Jackson, W. Jefferson, M. Stolinski, F. Shojaee-Moradie, R. Hovorka, A. M. Umpleby, and D. Russell- Jones. 2009. Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. Diabet. Med. 26:532-539.
65. Miyazaki, Y., A. Mahankali, E. Wajcberg, M. Bajaj, L. J. Mandarino, and R. A. DeFronzo. 2004. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89:4312-4319. (Pubitemid 39244431)
66. Yamanouchi, T., T. Sakai, K. Igarashi, K. Ichiyanagi, H. Watanabe, and T. Kawasaki. 2005. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet. Med. 22:980-985. (Pubitemid 41025992)
67. Rajagopalan, R., Y. Xu, and M. Abbadessa. 2006. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials. Am. J. Geriatr. Pharmacother. 4:123-133. (Pubitemid 44069474)
68. Abbasi, F., Y. D. Chen, H. M. Farin, C. Lamendola, and G. M. Reaven. 2008. Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects. Am. J. Cardiol. 102:64-69.
69. Diabetes Atorvastin Lipid Intervention (DALI) Study Group. 2001. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a doubleblind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 24:1335-1341.
70. Brochu-Gaudreau, K., C. Rehfeldt, R. Blouin, V. Bordignon, B. D. Murphy, and M. F. Palin. 2010. Adiponectin action from head to toe. Endocrine. 37:11-32.
71. Berg, A. H., T. P. Combs, X. Du, M. Brownlee, and P. E. Scherer. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7:947-953. (Pubitemid 32756433)
72. Xu, A., S. Yin, L. Wong, K. W. Chan, and K. S. Lam. 2004. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology. 145:487-494. (Pubitemid 38183790)
73. Miyazaki, Y., and R. A. DeFronzo. 2008. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes. Metab. 10:1204-1211.
74. Manning, P. J., W. H. Sutherland, R. J. Walker, S. M. Williams, S. A. de Jong, and E. A. Berry. 2008. The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals. Diabetes Res. Clin. Pract. 81:209-215.
75. Barac, A., U. Campia, L. A. Matuskey, L. Lu, and J. A. Panza. 2008. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Am. J. Cardiol. 101:980-985.
76. Pfützner, A., N. Marx, G. Lubben, M. Langenfeld, D. Walcher, T. Konrad, and T. Forst. 2005. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J. Am. Coll. Cardiol. 45:1925-1931. (Pubitemid 40814110)
77. Forst, T., A. Pfützner, G. Lubben, M. Weber, N. Marx, E. Karagiannis, C. Koehler, W. Baurecht, C. Hohberg, and M. Hanefeld. 2007. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism. 56:491-496. (Pubitemid 46437254)
78. Eguchi, K., H. Tomizawa, J. Ishikawa, S. Hoshide, T. Numao, T. Fukuda, K. Shimada, and K. Kario. 2007. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens. Res. 30:23-30.
79. Dorkhan, M., A. Frid, and L. Groop. 2008. Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add-insulin glargine or pioglitazone? Diabetes Res. Clin. Pract. 82:340-345.
80. Foryst-Ludwig, A., M. Hartge, M. Clemenz, C. Sprang, K. Hess, N. Marx, T. Unger, and U. Kintscher. 2010. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc. Diabetol. 9:64.
81. Ohman, M. K., Y. Shen, C. I. Obimba, A. P. Wright, M. Warnock, D. A. Lawrence, and D. T. Eitzman. 2008. Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation. 117:798-805. (Pubitemid 351640681)
82. Permana, P. A., W. Zhang, M. Wabitsch, P. Fischer-Posovszky, W. C. Duckworth, and P. D. Reaven. 2009. Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/ macrophages. Am. J. Physiol. Endocrinol. Metab. 296:E1076-E1084.
83. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391:79-82. (Pubitemid 28079218)
84. Derosa, G., A. D'Angelo, P. D. Ragonesi, L. Ciccarelli, M. N. Piccinni, F. Pricolo, S. A. Salvadeo, L. Montagna, A. Gravina, I. Ferrari, et al. 2007. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern. Med. J. 37:79-86. (Pubitemid 46066616)
85. Orasanu, G., O. Ziouzenkova, P. R. Devchand, V. Nehra, O. Hamdy, E. S. Horton, and J. Plutzky. 2008. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J. Am. Coll. Cardiol. 52:869-881.
86. Qin, S., T. Liu, V. S. Kamanna, and M. L. Kashyap. 2007. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler. Thromb. Vasc. Biol. 27:2428-2434. (Pubitemid 350203960)
87. Ogata, M., M. Tsujita, M. A. Hossain, N. Akita, F. J. Gonzalez, B. Staels, S. Suzuki, T. Fukutomi, G. Kimura, and S. Yokoyama. 2009. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 205:413-419.
88. Pedersen, T. R., A. G. Olsson, O. Faergeman, J. Kjekshus, H. Wedel, K. Berg, L. Wilhelmsen, T. Haghfelt, G. Thorgeirsson, K. Pyorala, et al. 1998. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1453-1460. (Pubitemid 28191300)
89. Davidson, M., P. M. Meyer, S. Haffner, S. Feinstein, R. D'Agostino, Sr., G. T. Kondos, A. Perez, Z. Chen, and T. Mazzone. 2008. Increased high-density lipoprotein cholesterol predicts the pioglitazone- mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 117:2123-2130. (Pubitemid 351572171)
90. Nicholls, S. J., E. M. Tuzcu, K. Wolski, O. Bayturan, A. Lavoie, K. Uno, S. Kupfer, A. Perez, R. Nesto, and S. E. Nissen. 2011. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. J. Am. Coll. Cardiol. 57:153-159.
91. Yki-Järvinen, H. 2004. Thiazolidinediones. N. Engl. J. Med. 351: 1106-1118.
92. Dormandy, J. A., B. Charbonnel, D. J. Eckland, E. Erdmann, M. Massi-Benedetti, I. K. Moules, A. M. Skene, M. H. Tan, P. J. Lefebvre, G. D. Murray, et al. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 366:1279-1289. (Pubitemid 41416583)
93. Lachin, J. M., G. Viberti, B. Zinman, S. M. Haffner, R. P. Aftring, G. Paul, B. G. Kravitz, W. H. Herman, R. R. Holman, and S. E. Kahn. 2011. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin. J. Am. Soc. Nephrol. 6:1032-1040.
94. Home, P. D., S. J. Pocock, H. Beck-Nielsen, P. S. Curtis, R. Gomis, M. Hanefeld, N. P. Jones, M. Komajda, and J. J. McMurray. 2009. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 373:2125-2135.
95. Komajda, M., P. Curtis, M. Hanefeld, H. Beck-Nielsen, S. J. Pocock, A. Zambanini, N. P. Jones, R. Gomis, and P. D. Home. 2008. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc. Diabetol. 7:10.
96. Haider, A. W., M. G. Larson, S. S. Franklin, and D. Levy. 2003. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann. Intern. Med. 138:10-16. (Pubitemid 36232089)
97. Marx, N., T. Bourcier, G. K. Sukhova, P. Libby, and J. Plutzky. 1999. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19:546-551. (Pubitemid 29135154)
98. Desouza, C. V., F. G. Hamel, K. Bidasee, and K. O'Connell. 2011. Role of inflammation and insulin resistance in endothelial progenitor cell dysfunction. Diabetes. 60:1286-1294.
99. Fadini, G. P., S. Sartore, C. Agostini, and A. Avogaro. 2007. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care. 30:1305-1313. (Pubitemid 46684670)
100. Jialal, I., S. Devaraj, U. Singh, and B. A. Huet. 2010. Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: implications for increased cardiovascular risk. Atherosclerosis. 211:297-302.
101. Liao, Y. F., L. L. Chen, T. S. Zeng, Y. M. Li, Y. Fan, L. J. Hu, and Y. Ling. 2010. Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes. Vasc. Med. 15:279-285.
102. Hannan, K. M., R. J. Dilley, S. T. de Dios, and P. J. Little. 2003. Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arterioscler. Thromb. Vasc. Biol. 23:762-768. (Pubitemid 36566164)
103. Makino, H., S. Okada, A. Nagumo, T. Sugisawa, Y. Miyamoto, I. Kishimoto, T. K. Akie, T. Soma, A. Taguchi, and Y. Yoshimasa. 2008. Pioglitazone treatment stimulates circulating CD34-positive cells in type 2 diabetes patients. Diabetes Res. Clin. Pract. 81: 327-330.
104. Pistrosch, F., K. Herbrig, U. Oelschlaegel, S. Richter, J. Passauer, S. Fischer, and P. Gross. 2005. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis. 183:163-167. (Pubitemid 41416835)
105. Sorrentino, S. A., F. H. Bahlmann, C. Besler, M. Muller, S. Schulz, N. Kirchhoff, C. Doerries, T. Horvath, A. Limbourg, F. Limbourg, et al. 2007. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 116:163-173. (Pubitemid 47057522)
106. Werner, C., C. H. Kamani, C. Gensch, M. Bohm, and U. Laufs. 2007. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes. 56:2609-2615. (Pubitemid 47523269)
107. Boyle, J. G., P. J. Logan, M. A. Ewart, J. A. Reihill, S. A. Ritchie, J. M. Connell, S. J. Cleland, and I. P. Salt. 2008. Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J. Biol. Chem. 283:11210-11217.
108. Mittermayer, F., G. Schaller, J. Pleiner, K. Krzyzanowska, S. Kapiotis, M. Roden, and M. Wolzt. 2007. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J. Clin. Endocrinol. Metab. 92:2574-2580. (Pubitemid 47037360)
109. Wong, W. T., X. Y. Tian, A. Xu, J. Yu, C. W. Lau, R. L. Hoo, Y. Wang, V. W. Lee, K. S. Lam, P. M. Vanhoutte, et al. 2011. Adiponectin is required for PPARgamma-mediated improvement of endothelial function in diabetic mice. Cell Metab. 14:104-115.
110. Fernandez, M., C. Triplitt, E. Wajcberg, A. A. Sriwijilkamol, N. Musi, K. Cusi, R. DeFronzo, and E. Cersosimo. 2008. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care. 31:121-127.
111. Patel, S. R., L. M. Mailloux, J. T. Coppola, C. Mindrescu, and C. S. Staniloae. 2008. Pioglitazone increases adiponectin levels in non-diabetic patients with coronary artery disease. Coron. Artery Dis. 19: 349-353.
112. Tsuchiya, K., I. Akaza, T. Yoshimoto, and Y. Hirata. 2009. Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. Endocr. J. 56:691-698.
113. Wöhrle, J., N. Marx, W. Koenig, V. Hombach, H. A. Kestler, M. Hoher, and T. Nusser. 2008. Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. Clin. Res. Cardiol. 97:726-733.
114. Kitahara, H., Y. Kobayashi, Y. Iwata, Y. Fujimoto, and I. Komuro. 2011. Effect of pioglitazone on endothelial dysfunction after sirolimus- eluting stent implantation. Am. J. Cardiol. 108:214-219.
115. Little, P. J., N. Osman, S. T. de Dios, N. Cemerlang, M. Ballinger, and J. Nigro. 2007. Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions. Cardiovasc. Diabetol. 6:33.
116. Law, R. E., S. Goetze, X. P. Xi, S. Jackson, Y. Kawano, L. Demer, M. C. Fishbein, W. P. Meehan, and W. A. Hsueh. 2000. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation. 101:1311-1318. (Pubitemid 30158620)
117. Hong, S. J., S. T. Kim, T. J. Kim, E. O. Kim, C. M. Ahn, J. H. Park, J. S. Kim, K. M. Lee, and D. S. Lim. 2010. Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus- eluting stent implantation. Arterioscler. Thromb. Vasc. Biol. 30: 2655-2665.
118. de Dios, S. T., D. Bruemmer, R. J. Dilley, M. E. Ivey, G. L. Jennings, R. E. Law, and P. J. Little. 2003. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation. 107: 2548-2550. (Pubitemid 36628933)
119. Geng, D. F., D. M. Jin, W. Wu, Z. Wang, and J. F. Wang. 2009. Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials. Atherosclerosis. 202:521-528.
120. Patel, D., B. Walitt, J. Lindsay, and R. L. Wilensky. 2011. Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis. JACC Cardiovasc. Interv. 4:353-360.
121. Riche, D. M., R. Valderrama, and N. N. Henyan. 2007. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care. 30:384-388. (Pubitemid 46198353)
122. Cao, Z., and Y. Zhou. 2008. Thiazolidinediones may be effective in the prevention of stent thrombosis with DES. Med. Hypotheses. 70: 329-332.
123. Babaev, V. R., P. G. Yancey, S. V. Ryzhov, V. Kon, M. D. Breyer, M. A. Magnuson, S. Fazio, and M. F. Linton. 2005. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25:1647-1653. (Pubitemid 41098935)
124. Chawla, A., W. A. Boisvert, C. H. Lee, B. A. Laffitte, Y. Barak, S. B. Joseph, D. Liao, L. Nagy, P. A. Edwards, L. K. Curtiss, et al. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7:161-171. (Pubitemid 32162909)
125. Vucic, E., S. D. Dickson, C. Calcagno, J. H. Rudd, E. Moshier, K. Hayashi, J. S. Mounessa, M. Roytman, M. J. Moon, J. Lin, et al. 2011. Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc. Imaging. 4:1100-1109.
126. Soumian, S., R. Gibbs, A. Davies, and C. Albrecht. 2005. mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease. J. Clin. Pathol. 58:1255-1260. (Pubitemid 41752768)
127. Sueyoshi, S., M. Mitsumata, Y. Kusumi, M. Niihashi, M. Esumi, T. Yamada, and I. Sakurai. 2010. Increased expression of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma in human atherosclerosis. Pathol. Res. Pract. 206:429-438.
128. Bouhlel, M. A., B. Derudas, E. Rigamonti, R. Dievart, J. Brozek, S. Haulon, C. Zawadzki, B. Jude, G. Torpier, N. Marx, et al. 2007. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6: 137-143. (Pubitemid 47189091)
129. Lonn, E. M., H. C. Gerstein, P. Sheridan, S. Smith, R. Diaz, V. Mohan, J. Bosch, S. Yusuf, and G. R. Dagenais. 2009. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J. Am. Coll. Cardiol. 53:2028-2035.
130. Mazzone, T., P. M. Meyer, S. B. Feinstein, M. H. Davidson, G. T. Kondos, R. B. D'Agostino, Sr., A. Perez, J. C. Provost, and S. M. Haffner. 2006. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 296:2572-2581. (Pubitemid 44903861)
131. Davidson, M. H., C. A. Beam, S. Haffner, A. Perez, R. D'Agostino, Sr., and T. Mazzone. 2010. Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study. Arterioscler. Thromb. Vasc. Biol. 30:1873-1876.
132. Webb, D. R., M. J. Davies, L. J. Gray, K. R. Abrams, B. Srinivasan, S. Das, N. Taub, I. Lawrence, S. Sutton, and K. Khunti. 2010. Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones. Diabetes Obes. Metab. 12:124-132.
133. Nissen, S. E., S. J. Nicholls, K. Wolski, R. Nesto, S. Kupfer, A. Perez, H. Jure, R. De Larochelliere, C. S. Staniloae, K. Mavromatis, et al. 2008. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 299:1561-1573. (Pubitemid 351482795)
134. You, S. H., B. S. Kim, S. J. Hong, C. M. Ahn, and D. S. Lim. 2010. The effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients: prospective randomized study with volumetric intravascular ultrasonography analysis. Korean Circ. J. 40:625-631.
135. Yang, H. B., X. Y. Zhao, J. Y. Zhang, Y. Y. Du, and X. F. Wang. 2012. Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance. Diabet. Med. 29: 359-365.
136. Ogasawara, D., J. Shite, T. Shinke, S. Watanabe, H. Otake, Y. Tanino, T. Sawada, H. Kawamori, H. Kato, N. Miyoshi, et al. 2009. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ. J. 73:343-351.
137. Nakayama, T., N. Komiyama, M. Yokoyama, S. Namikawa, N. Kuroda, Y. Kobayashi, and I. Komuro. 2010. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int. J. Cardiol. 138:157-165.
138. Bertrand, O. F., P. Poirier, J. Rodes-Cabau, S. Rinfret, L. M. Title, V. Dzavik, M. Natarajan, J. Angel, N. Batalla, N. Almeras, et al. 2010. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: a randomized placebo-controlled clinical trial. Atherosclerosis. 211:565-573.
139. Gerstein, H. C., R. E. Ratner, C. P. Cannon, P. W. Serruys, H. M. Garcia-Garcia, G. A. van Es, N. S. Kolatkar, B. G. Kravitz, D. M. Miller, C. Huang, et al. 2010. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. 121:1176-1187.
140. Yue, T. L., W. Bao, J. L. Gu, J. Cui, L. Tao, X. L. Ma, E. H. Ohlstein, and B. M. Jucker. 2005. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes. 54:554-562.
141. Yue Tl, T. L., J. Chen, W. Bao, P. K. Narayanan, A. Bril, W. Jiang, P. G. Lysko, J. L. Gu, R. Boyce, D. M. Zimmerman, et al. 2001. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 104:2588-2594. (Pubitemid 33104798)
142. Yasuda, S., H. Kobayashi, M. Iwasa, I. Kawamura, S. Sumi, B. Narentuoya, T. Yamaki, H. Ushikoshi, K. Nishigaki, K. Nagashima, et al. 2009. Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 296:H1558-H1565.
143. Wynne, A. M., M. M. Mocanu, and D. M. Yellon. 2005. Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK. J. Cardiovasc. Pharmacol. 46:817-822. (Pubitemid 44378255)
144. Sidell, R. J., M. A. Cole, N. J. Draper, M. Desrois, R. E. Buckingham, and K. Clarke. 2002. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes. 51:1110-1117. (Pubitemid 34438357)
145. Molavi, B., J. Chen, and J. L. Mehta. 2006. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am. J. Physiol. Heart Circ. Physiol. 291:H687-H693. (Pubitemid 44175074)
146. Lotz, C., M. Lange, A. Redel, J. Stumpner, J. Schmidt, T. Tischer-Zeitz, N. Roewer, and F. Kehl. 2011. Peroxisome-proliferator-activated receptor gamma mediates the second window of anaesthetic-induced preconditioning. Exp. Physiol. 96:317-324.
147. Liu, H. R., L. Tao, E. Gao, Y. Qu, W. B. Lau, B. L. Lopez, T. A. Christopher, W. Koch, T. L. Yue, and X. L. Ma. 2009. Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation-a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc. Res. 81:344-352.
148. Khandoudi, N., P. Delerive, I. Berrebi-Bertrand, R. E. Buckingham, B. Staels, and A. Bril. 2002. Rosiglitazone, a peroxisome proliferator- activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes. 51:1507-1514. (Pubitemid 34826618)
149. Cao, Z., P. Ye, C. Long, K. Chen, X. Li, and H. Wang. 2007. Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats. Pharmacology. 79: 184-192. (Pubitemid 46631932)
150. Lee, T. M., and T. F. Chou. 2003. Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins. Am. J. Physiol. Heart Circ. Physiol. 285: H1650-H1659.
151. Zhu, P., L. Lu, Y. Xu, and G. G. Schwartz. 2000. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation. 101:1165-1171. (Pubitemid 30146619)
152. Geng, D. F., W. Wu, D. M. Jin, J. F. Wang, and Y. M. Wu. 2006. Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int. J. Cardiol. 113:86-91. (Pubitemid 44648366)
153. Shiomi, T., H. Tsutsui, S. Hayashidani, N. Suematsu, M. Ikeuchi, J. Wen, M. Ishibashi, T. Kubota, K. Egashira, and A. Takeshita. 2002. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 106:3126-3132. (Pubitemid 35440299)
154. Frantz, S., K. Hu, J. Widder, B. Bayer, C. C. Witzel, I. Schmidt, P. Galuppo, J. Strotmann, G. Ertl, and J. Bauersachs. 2004. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br. J. Pharmacol. 141:9-14. (Pubitemid 38241158)
155. Lygate, C. A., K. Hulbert, M. Monfared, M. A. Cole, K. Clarke, and S. Neubauer. 2003. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc. Res. 58:632-637. (Pubitemid 36700421)
156. Pereira, M. P., O. Hurtado, A. Cardenas, D. Alonso-Escolano, L. Bosca, J. Vivancos, F. Nombela, J. C. Leza, P. Lorenzo, I. Lizasoain, et al. 2005. The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J. Neuropathol. Exp. Neurol. 64:797-805. (Pubitemid 41285813)
157. Sobrado, M., M. P. Pereira, I. Ballesteros, O. Hurtado, D. Fernandez- Lopez, J. M. Pradillo, J. R. Caso, J. Vivancos, F. Nombela, J. Serena, et al. 2009. Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J. Neurosci. 29:3875-3884.
158. Tureyen, K., R. Kapadia, K. K. Bowen, I. Satriotomo, J. Liang, D. L. Feinstein, and R. Vemuganti. 2007. Peroxisome proliferatoractivated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. Neurochem. 101:41-56. (Pubitemid 46426485)
159. Wu, J. S., W. M. Cheung, Y. S. Tsai, Y. T. Chen, W. H. Fong, H. D. Tsai, Y. C. Chen, J. Y. Liou, S. K. Shyue, J. J. Chen, et al. 2009. Ligand-activated peroxisome proliferator-activated receptorgamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation. 119: 1124-1134.
160. Zhang, H. L., M. Xu, C. Wei, A. P. Qin, C. F. Liu, L. Z. Hong, X. Y. Zhao, J. Liu, and Z. H. Qin. 2011. Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-kappaB signaling pathway. Neuroscience. 176:381-395.
161. Zhao, Y., A. Patzer, P. Gohlke, T. Herdegen, and J. Culman. 2005. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur. J. Neurosci. 22:278-282. (Pubitemid 41059994)
162. de Boer, R. A., F. M. Martens, I. Kuipers, F. Boomsma, and F. L. Visseren. 2010. The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus. J. Hum. Hypertens. 24:74-76.
163. Narang, N., S. I. Armstead, A. Stream, S. M. Abdullah, R. See, P. G. Snell, J. McGavock, C. R. Ayers, M. O. Gore, A. Khera, et al. 2011. Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment. Diab. Vasc. Dis. Res. 8:101-108.
164. Ogawa, S., K. Takeuchi, and S. Ito. 2003. Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J. Clin. Endocrinol. Metab. 88:3993-3996. (Pubitemid 37034557)
165. Kim, H. J., E. S. Kang, D. J. Kim, S. H. Kim, C. W. Ahn, B. S. Cha, M. Nam, C. H. Chung, K. W. Lee, C. M. Nam, et al. 2007. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin. Endocrinol. (Oxf.). 66:282-289. (Pubitemid 46096150)
166. Zhang, H., A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang. 2005. Collecting duct-specific deletion of peroxisome proliferator- activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. USA. 102:9406-9411. (Pubitemid 40923576)
167. Mudaliar, S., A. R. Chang, V. R. Aroda, E. Chao, P. Burke, S. Baxi, K. A. Griver, D. T. O'Connor, and R. R. Henry. 2010. Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes. Diabetes Obes. Metab. 12:133-138.
168. Karalliedde, J., R. Buckingham, M. Starkie, D. Lorand, M. Stewart, and G. Viberti. 2006. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J. Am. Soc. Nephrol. 17: 3482-3490. (Pubitemid 44865290)
169. Guan, Y., C. Hao, D. R. Cha, R. Rao, W. Lu, D. E. Kohan, M. A. Magnuson, R. Redha, Y. Zhang, and M. D. Breyer. 2005. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11: 861-866. (Pubitemid 41161118)
170. Artunc, F., D. Sandulache, O. Nasir, K. M. Boini, B. Friedrich, N. Beier, E. Dicks, S. Potzsch, K. Klingel, K. Amann, et al. 2008. Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPARgamma agonist pioglitazone. Pflugers Arch. 456:425-436.
171. Endo, Y., M. Suzuki, H. Yamada, S. Horita, M. Kunimi, O. Yamazaki, A. Shirai, M. Nakamura, O. Iso, Y. Li, et al. 2011. Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARgamma-dependent nongenomic signaling. Cell Metab. 13:550-561.
172. Xu, Y., M. Gen, L. Lu, J. Fox, S. O. Weiss, R. D. Brown, D. Perlov, H. Ahmad, P. Zhu, C. Greyson, et al. 2005. PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am. J. Physiol. Heart Circ. Physiol. 288:H1314-H1323. (Pubitemid 40270039)
173. Dargie, H. J., P. R. Hildebrandt, G. A. Riegger, J. J. McMurray, S. O. McMorn, J. N. Roberts, A. Zambanini, and J. P. Wilding. 2007. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J. Am. Coll. Cardiol. 49: 1696-1704. (Pubitemid 46589926)
174. Naka, K. K., K. Pappas, K. Papathanassiou, N. D. Papamichael, N. Kazakos, C. Kanioglou, D. Makriyiannis, C. S. Katsouras, K. Liveris, A. Tsatsoulis, et al. 2010. Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study. Cardiovasc. Diabetol. 9:57.
175. Von Bibra, H., M. Diamant, P. G. Scheffer, T. Siegmund, and P. M. Schumm-Draeger. 2008. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diab. Vasc. Dis. Res. 5:310-318.
176. Ordu, S., H. Ozhan, R. Alemdar, M. Aydin, C. Basar, O. Caglar, M. Yazici, and S. Yalcin. 2010. Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study. Acta Cardiol. 65:401-406.
177. Horio, T., M. Suzuki, K. Suzuki, I. Takamisawa, A. Hiuge, K. Kamide, S. Takiuchi, Y. Iwashima, S. Kihara, T. Funahashi, et al. 2005. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am. J. Hypertens. 18: 949-957. (Pubitemid 41040266)
178. Acton III, J. J., T. E. Akiyama, C. H. Chang, L. Colwell, S. Debenham, T. Doebber, M. Einstein, K. Liu, M. E. McCann, D. E. Moller, et al. 2009. Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl) carbonyl]-2-methyl-6- (trifluoromethoxy)-1H- indol-1-yl}phenoxy) butanoic acid (MK-0533): a novel selective peroxisome proliferator- activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume. J. Med. Chem. 52:3846-3854.
179. Kim, M. K., Y. N. Chae, S. H. Choi, H. S. Moon, M. H. Son, M. H. Bae, H. H. Choi, Y. Hur, E. Kim, Y. H. Park, et al. 2011. PAM-1616, a selective peroxisome proliferator-activated receptor gamma modulator with preserved anti-diabetic efficacy and reduced adverse effects. Eur. J. Pharmacol. 650:673-681.
180. Szentandrássy, N., G. Harmati, L. Barandi, J. Simko, B. Horvath, J. Magyar, T. Banyasz, I. Lorincz, A. Szebeni, V. Kecskemeti, et al. 2011. Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells. Br. J. Pharmacol. 163:499-509.
181. Sunaga, Y., N. Inagaki, T. Gonoi, Y. Yamada, H. Ishida, Y. Seino, and S. Seino. 1999. Troglitazone but not pioglitazone affects ATP-sensitive K(+) channel activity. Eur. J. Pharmacol. 381:71-76. (Pubitemid 29488591)
182. Rowe, I. C., K. Lee, R. N. Khan, and M. L. Ashford. 1997. Effect of englitazone on KATP and calcium-activated non-selective cation channels in CRI-G1 insulin-secreting cells. Br. J. Pharmacol. 121: 531-539. (Pubitemid 27226307)
183. McKay, N. G., J. M. Kinsella, C. M. Campbell, and M. L. Ashford. 2000. Sensitivity of Kir6.2-SUR1 currents, in the absence and presence of sodium azide, to the K(ATP) channel inhibitors, ciclazindol and englitazone. Br. J. Pharmacol. 130:857-866. (Pubitemid 30389066)
184. Lee, K., T. Ibbotson, P. J. Richardson, and P. R. Boden. 1996. Inhibition of KATP channel activity by troglitazone in CRI-G1 insulin-secreting cells. Eur. J. Pharmacol. 313:163-167. (Pubitemid 26342221)
185. Lee, K., and P. Boden. 1997. Troglitazone inhibits type 2KATP channel activity and depolarises tolbutamide-sensitive neurones in the rat ventromedial hypothalamus. Brain Res. 751:165-168. (Pubitemid 27122151)
186. Chang, T. J., W. P. Chen, C. Yang, P. H. Lu, Y. C. Liang, M. J. Su, S. C. Lee, and L. M. Chuang. 2009. Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazoneinduced closure of the K(ATP) channel and insulin secretion in rats. Diabetologia. 52:1112-1121.
187. Charbonnel, B., J. Dormandy, E. Erdmann, M. Massi-Benedetti, and A. Skene. 2004. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 27:1647-1653. (Pubitemid 38857439)
188. Charbonnel, B., R. DeFronzo, J. Davidson, O. Schmitz, K. Birkeland, V. Pirags, and A. Scheen. 2010. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J. Clin. Endocrinol. Metab. 95:2163-2171.
189. Erdmann, E., J. A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I. K. Moules, and A. M. Skene. 2007. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J. Am. Coll. Cardiol. 49:1772-1780. (Pubitemid 46629127)
190. Dagenais, G. R., H. C. Gerstein, R. Holman, A. Budaj, A. Escalante, T. Hedner, M. Keltai, E. Lonn, S. McFarlane, M. McQueen, et al. 2008. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 31:1007-1014.
191. Gerstein, H. C., S. Yusuf, J. Bosch, J. Pogue, P. Sheridan, N. Dinccag, M. Hanefeld, B. Hoogwerf, M. Laakso, V. Mohan, et al. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 368:1096-1105.
192. DeFronzo, R. A., D. Tripathy, D. C. Schwenke, M. Banerji, G. A. Bray, T. A. Buchanan, S. C. Clement, R. R. Henry, H. N. Hodis, A. E. Kitabchi, et al. 2011. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 364:1104-1115.
193. Kahn, S. E., S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. Lachin, M. C. O'Neill, B. Zinman, et al. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355: 2427-2443. (Pubitemid 44903747)
194. Lincoff, A. M., K. Wolski, S. J. Nicholls, and S. E. Nissen. 2007. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 298:1180-1188. (Pubitemid 47403104)
195. Mannucci, E., M. Monami, C. Lamanna, G. F. Gensini, and N. Marchionni. 2008. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 10:1221-1238.
196. Nissen, S. E., and K. Wolski. 2010. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170:1191-1201.
197. Woodcock, J., J. M. Sharfstein, and M. Hamburg. 2010. Regulatory action on rosiglitazone by the US Food and Drug Administration. N. Engl. J. Med. 363:1489-1491.
198. Ziyadeh, N., A. T. McAfee, C. Koro, J. Landon, and C. K. Arnold. 2009. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clin. Ther. 31:2665-2677.
199. Winkelmayer, W. C., S. Setoguchi, R. Levin, and D. H. Solomon. 2008. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch. Intern. Med. 168:2368-2375.
200. Tzoulaki, I., M. Molokhia, V. Curcin, M. P. Little, C. J. Millett, A. Ng, R. I. Hughes, K. Khunti, M. R. Wilkins, A. Majeed, et al. 2009. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 339:b4731.
201. Lipscombe, L. L., T. Gomes, L. E. Levesque, J. E. Hux, D. N. Juurlink, and D. A. Alter. 2007. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 298: 2634-2643. (Pubitemid 350254955)
202. Hsiao, F. Y., W. F. Huang, Y. W. Wen, P. F. Chen, K. N. Kuo, and Y. W. Tsai. 2009. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf. 32:675-690.
203. Habib, Z. A., L. Tzogias, S. L. Havstad, K. Wells, G. Divine, D. E. Lanfear, J. Tang, R. Krajenta, M. Pladevall, and L. K. Williams. 2009. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol. Drug Saf. 18:437-447.
204. Loke, Y. K., C. S. Kwok, and S. Singh. 2011. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 342:d1309.
205. Sears, D. D., A. Hsiao, J. M. Ofrecio, J. Chapman, W. He, and J. M. Olefsky. 2007. Selective modulation of promoter recruitment and transcriptional activity of PPARgamma. Biochem. Biophys. Res. Commun. 364:515-521. (Pubitemid 350026497)
206. Dunn, F. L., L. S. Higgins, J. Fredrickson, and A. M. DePaoli. 2011. Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. J. Diabetes Complications. 25:151-158.
207. Kong, A. P., A. Yamasaki, R. Ozaki, H. Saito, T. Asami, S. Ohwada, G. T. Ko, C. K. Wong, G. T. Leung, K. F. Lee, et al. 2011. A randomized- controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes. Metab. 13:806-813.
208. Henriksen, K., I. Byrjalsen, P. Qvist, H. Beck-Nielsen, G. Hansen, B. J. Riis, H. Perrild, O. L. Svendsen, J. Gram, M. A. Karsdal, et al. 2011. Efficacy and safety of the PPARgamma partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab. Res. Rev. 27:392-401.
209. Choi, J. H., A. S. Banks, J. L. Estall, S. Kajimura, P. Bostrom, D. Laznik, J. L. Ruas, M. J. Chalmers, T. M. Kamenecka, M. Bluher, et al. 2010. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by CDK5. Nature. 466:451-456.
210. Choi, J. H., A. S. Banks, T. M. Kamenecka, S. A. Busby, M. J. Chalmers, N. Kumar, D. S. Kuruvilla, Y. Shin, Y. He, J. B. Bruning, et al. 2011. Antidiabetic actions of a non-agonist PPARgamma ligand blocking CDK5-mediated phosphorylation. Nature. 477: 477-481.
211. Balakumar, P., M. Rose, S. S. Ganti, P. Krishan, and M. Singh. 2007. PPAR dual agonists: are they opening Pandora's Box? Pharmacol. Res. 56:91-98. (Pubitemid 47304493)
212. Nissen, S. E., K. Wolski, and E. J. Topol. 2005. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 294:2581-2586. (Pubitemid 41697247)
213. Oleksiewicz, M. B., J. Southgate, L. Iversen, and F. L. Egerod. 2008. Rat urinary bladder carcinogenesis by dual-acting PPARalpha + gamma agonists. PPAR Res. 2008:103167.
214. Younk, L. M., L. Uhl, and S. N. Davis. 2011. Pharmacokinetics, effi cacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin. Drug Metab. Toxicol. 7: 753-763.
215. Caccamo, G., F. Bonura, F. Bonura, G. Vitale, G. Novo, S. Evola, G. Evola, M. R. Grisanti, and S. Novo. 2010. Insulin resistance and acute coronary syndrome. Atherosclerosis. 211:672-675.
216. Kernan, W. N., S. E. Inzucchi, C. M. Viscoli, L. M. Brass, D. M. Bravata, G. I. Shulman, J. C. McVeety, and R. I. Horwitz. 2003. Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke. Neurology. 60:1447-1451. (Pubitemid 36554804)
217. Charbonnel, B. 2009. PPAR-alpha and PPAR-gamma agonists for type 2 diabetes. Lancet. 374:96-98.